QualityStocks would like to highlight Advanced Cell Technology, Inc. (OTCBB: ACTC), a biotechnology company applying cellular technology in the field of regenerative medicine. ACT specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.
In the company’s news last week,
Advanced Cell Technology reported the successful completion of the dosing of the third patient in its phase I/II trial for dry age-related macular degeneration (AMD) using retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs).
The company has already conducted the procedure in six other patients at UCLA, and said it anticipates adding more sites in the near future. Gary Rabin, chairman and CEO of ACT, also noted the prestige of individuals participating in the trials.
“The completion of enrollment of the first cohort of patients in our dry AMD clinical trial is a significant step forward in our RPE clinical program. The first six patients in the U.S. trials have all been treated at UCLA, and as we have recently announced, the trials should soon expand to additional sites,” Rabin stated in the press release. “As we have built our clinical team, we have been fortunate to have attracted the attention of some of the highest-caliber ophthalmologists and related institutions in the U.S. and Europe and recognize the huge value that their expertise provides us as we plan for the future of our therapeutic programs. With their guidance, we have also worked with the FDA to successfully expand the criteria of eligibility for patients to participate in our dry AMD trial.”
The procedures at UCLA were all conducted by the team led by Steven Schwartz, M.D., Ahmanson, professor of ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA’s Jules Stein Eye Institute.
Dr. Schwartz reports that there have been no complications with any of the procedures, nor have there been any safety issues.
ACT currently is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells as treatment for various forms of macular degeneration.
“We are extremely pleased with the progress being made in all three of our clinical trials here in the U.S. and the UK,” stated Robert Lanza, M.D., ACT’s chief scientific officer. “The data we are reviewing seems to be pointing in the appropriate direction. … We still have many patients left to treat during the course of these trials, but our team remains hopeful that stem cell-derived RPE cells may someday provide a new therapeutic approach for the treatment of many forms of macular degeneration. We hear from patients who suffer from these diseases on nearly a daily basis, and appreciate the huge responsibility we have to them.”
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.